If approved, tapinarof's main rival will be Amgen and its oral PDE4 inhibitor Otezla (apremilast) – acquired for $13.4 billion in 2019 in side deal to Bristol-Myers Squibb's $74 billion takeover ...

Results from the POETYK PSO-1 and POETYK PSO-2 showed that 58% and 53% respectively of patients treated with Sotyktu achieved 75% skin clearance, versus 35% and 40% for Otezla. BMS has set a list ...

Discover and Bank of America cards are currently not available on CNBC Select and links have been redirected to our credit card marketplace where you can review offers from other issuers like ...

*Displayed pricing includes all fees. Game times are subject to change.